CCND1 is altered in 4.48% of malignant solid tumor patients with CCND1 Amplification present in 3.98% of all malignant solid tumor patients [4].

CCND1 Amplification is an inclusion criterion in 10 clinical trials for malignant solid tumor, of which 9 are open and 1 is closed. Of the trials that contain CCND1 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (7 open) [5].

CCND1 is altered in 16.28% of breast carcinoma patients with CCND1 Amplification present in 12.6% of all breast carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 4 clinical trials for breast carcinoma, of which 2 are open and 2 are closed. Of the trials that contain CCND1 Amplification and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [5].

CCND1 is altered in 1.44% of colorectal carcinoma patients with CCND1 Amplification present in 0.79% of all colorectal carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [5].

CCND1 is altered in 4.86% of melanoma patients with CCND1 Amplification present in 4.74% of all melanoma patients [4].

CCND1 Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Amplification and melanoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND1 is altered in 2.54% of non-small cell lung carcinoma patients with CCND1 Amplification present in 2.16% of all non-small cell lung carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Amplification and non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND1 is altered in 3.14% of non-hodgkin lymphoma patients with CCND1 Amplification present in 0.88% of all non-hodgkin lymphoma patients [4].

CCND1 Amplification is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Amplification and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND1 is altered in 0.81% of soft tissue sarcoma patients with CCND1 Amplification present in 0.59% of all soft tissue sarcoma patients [4].

CCND1 Amplification is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Amplification and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND1 is altered in 1.02% of malignant glioma patients with CCND1 Amplification present in 0.2% of all malignant glioma patients [4].

CCND1 Amplification is an inclusion criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 Amplification and malignant glioma as inclusion criteria, 2 are early phase 1 (2 open) [5].

CCND1 is altered in 36.13% of esophageal squamous cell carcinoma patients with CCND1 Amplification present in 38.53% of all esophageal squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 31.25% of hypopharyngeal squamous cell carcinoma patients with CCND1 Amplification present in 35.71% of all hypopharyngeal squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 22.86% of laryngeal squamous cell carcinoma patients with CCND1 Amplification present in 24.62% of all laryngeal squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 17.97% of acral lentiginous melanoma patients with CCND1 Amplification present in 19.66% of all acral lentiginous melanoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 13.33% of oral cavity carcinoma patients with CCND1 Amplification present in 13.86% of all oral cavity carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 13.33% of oral cavity squamous cell carcinoma patients with CCND1 Amplification present in 13.86% of all oral cavity squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 12.3% of esophageal carcinoma patients with CCND1 Amplification present in 12.45% of all esophageal carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 is altered in 11.58% of head and neck squamous cell carcinoma patients with CCND1 Amplification present in 11.84% of all head and neck squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 10.33% of bladder carcinoma patients with CCND1 Amplification present in 10.39% of all bladder carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 8.92% of squamous cell lung carcinoma patients with CCND1 Amplification present in 8.41% of all squamous cell lung carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CCND1 is altered in 8.46% of adenocarcinoma of the gastroesophageal junction patients with CCND1 Amplification present in 8.36% of all adenocarcinoma of the gastroesophageal junction patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 7.83% of head and neck carcinoma patients with CCND1 Amplification present in 8.16% of all head and neck carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 6.05% of oropharyngeal squamous cell carcinoma patients with CCND1 Amplification present in 5.93% of all oropharyngeal squamous cell carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 4.86% of gallbladder carcinoma patients with CCND1 Amplification present in 4.29% of all gallbladder carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 4.24% of cancer patients with CCND1 Amplification present in 3.73% of all cancer patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Amplification and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 is altered in 2.81% of bile duct carcinoma patients with CCND1 Amplification present in 2.9% of all bile duct carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 3.17% of gastric adenocarcinoma patients with CCND1 Amplification present in 2.82% of all gastric adenocarcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 3.14% of gastric carcinoma patients with CCND1 Amplification present in 2.79% of all gastric carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 is altered in 2.37% of osteosarcoma patients with CCND1 Amplification present in 2.18% of all osteosarcoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 2.35% of prostate carcinoma patients with CCND1 Amplification present in 2.13% of all prostate carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CCND1 is altered in 2.51% of lung carcinoma patients with CCND1 Amplification present in 2.12% of all lung carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 2.03% of liposarcoma patients with CCND1 Amplification present in 1.86% of all liposarcoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CCND1 is altered in 1.73% of lung adenocarcinoma patients with CCND1 Amplification present in 1.34% of all lung adenocarcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and lung adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CCND1 is altered in 0.96% of pancreatic carcinoma patients with CCND1 Amplification present in 0.97% of all pancreatic carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 1.96% of cervical carcinoma patients with CCND1 Amplification present in 0.9% of all cervical carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 1.11% of ovarian carcinoma patients with CCND1 Amplification present in 0.76% of all ovarian carcinoma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 5.78% of malignant uterine neoplasm patients with CCND1 Amplification present in 0.74% of all malignant uterine neoplasm patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 0.27% of meningioma patients with CCND1 Amplification present in 0.3% of all meningioma patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND1 is altered in 0.14% of germ cell tumor patients [4].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Amplification and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND1 Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND1 Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].